COMPANY PROFILE
| Price and Volume | |
|---|---|
| Recent Price | 2.71 |
| 52 Week High | 3.15 |
| 52 Week Low | 0.35 |
| Avg. Daily Vol. (Mil) | 0.05 |
| Beta (3 year) | 1.44 |
| Share Related Items | |
| Mkt Cap (Mil) | 96.47 |
| Shares Out (Mil) | 35.60 |
| Float (Mil) | 32.86 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.70 |
| Current Ratio | 3.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | N.A. |
| Price/Sales | 59.62 |
| Price/Book | 13.31 |
| Price/Cash Flow | -9.20 |
| Per Share Data | |
| Earnings | -0.32 |
| Sales | 0.05 |
| Book Value | 0.20 |
| Cash Flow | -0.29 |
| Business Summary | |
|---|---|
| The Company develops proprietary DNA-based technologies for use in the detection of certain cancers. | |
| General Information | |
| 100 Campus Drive
Marlborough, MA 01752 |
|
| www.exactsciences.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 4 | |
| CEO: Kevin T. Conroy | |
| Short Interest | |
| Current Month (Mil) | 0.15 |
| Previous Month (Mil) | 0.16 |
| Short Interest Ratio (Days) | 3.70 |
| Management Effectiveness | |
| Return on Equity | N.A. |
| Return on Assets | -33.50 |
| Return on Investments | -129.00 |
| Profitability | |
| Gross Margin | N.A. |
| EBIT Margin | N.A. |
| Profit Margin | 0.00 |